Skip to main content

Day: February 5, 2024

Tyson Foods Reports First Quarter 2024 Results

Reports Third Quarter of Sequential Adjusted Operating Income Growth SPRINGDALE, Ark., Feb. 05, 2024 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:(in millions, except per share data) First Quarter    2024     2023Sales $ 13,319   $ 13,260       Operating Income $ 231   $ 467Adjusted1 Operating Income (non-GAAP) $ 411   $ 453       Net Income Per Share Attributable to Tyson $ 0.30   $ 0.88Adjusted1 Net Income Per Share Attributable to Tyson (non-GAAP) $ 0.69   $ 0.851 The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP)....

Continue reading

Form 8.3 – [SMART METERING PLC – 02 02 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree SMART METERING SYSTEMS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Nation’s fastest-growing passenger charter airline announces changes to its Board and Management Team

MIAMI, Feb. 05, 2024 (GLOBE NEWSWIRE) — Global Crossing Airlines Group, Inc. (JET: Cboe CA; JET.B: Cboe CA; JETMF: OTCQB) (“GlobalX”) announces the appointment, effective today, of Chris Jamroz as Executive Chairman and Ryan Goepel as President. Mr. Goepel will continue to serve as Chief Financial Officer. The Board of Directors (the “Board”) and Edward J. Wegel, the Company’s Chief Executive Officer, have agreed that Mr.Wegel will resign his duties, rights, and obligations as an officer and Chairman and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the Executive Chairman of the Board. Ed Wegel will continue to serve on GlobalX’s Board of Directors and as a GlobalX Senior Advisor. “It has been a great privilege for me to have helped build GlobalX...

Continue reading

Form 8.3 – [LXi REIT PLC – 02 02 2024) – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LXi REIT PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has been granted divisional patent approval by the China National Intellectual Property Administration. The granting of this latest patent establishes both the company’s patent protection around its flagship molecule as well as its extensive IP protection in the psychedelic space. Clearmind’s IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted...

Continue reading

Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company

Exclusive supply agreement for two of Avicanna’s proprietary topical products in the European region Right of first refusal agreement for the Avicanna’s SEDDs capsules in the European region TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce an exclusive supply agreement for two of the Company’s proprietary topical products with a multinational pharmaceutical company (“Pharma”). “We look forward to expanding our proprietary topical products into the European region and to be doing so through the utilization of our own international infrastructure for manufacturing. We are confident that through this...

Continue reading

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 02 02 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

– Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo Capital, as well two large investment management firms. – Pro forma cash and investments expected to fund current operating plan into late 2025. REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has agreed to sell approximately 106.25 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private...

Continue reading

One World Products Confirms That Its Colombian Cannabis Operations are Unaffected by Recent Regulatory Developments in Colombia

Recent Agreements Executed with Smokiez Edibles and the Marley Family’s Kx Family Care Are Expected to Ramp Operations in Early 2024 LAS VEGAS, NV , Feb. 05, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — One World Products, Inc. (the “Company,”) (OTCQB: OWPC), a fully-licensed hemp and cannabis producer in Colombia, today announced that its current business prospects are unaffected by recent regulatory and political hurdles in Colombia. With a business model primarily centered on international markets and medicinal applications, OWP remains insulated from the uncertainties surrounding the domestic Colombian THC market for recreational use. The Company’s products, which include a range of THC solutions provided through medical channels, are derived from cannabinoids sourced from hemp and are fully compliant with current...

Continue reading

Meso Numismatics Announces Intention to Undergo Name Change and Authorized Shares Change

LAS VEGAS, NV, Feb. 05, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company is pleased to announce that it will be undergoing a name change from Meso Numismatics Inc. to Regenerative Medical Technology Group Inc. to better reflect the company’s business. The Company will also change its authorized shares outstanding from the current 6.5 billion to 100 million shares. Please see the Information Statement on Schedule 14C filed by the Company on February 2, 2024, and other Company filings at www.sec.gov. About Meso Numismatics: Meso Numismatics Corp is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.